Milliman recently refreshed its analysis of commercial and Medicare outpatient drug spending at 340B participating hospitals. This new report, commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA), builds on previous research by the Government Accountability Office (GAO) and Milliman. In June 2015, the GAO published a study comparing Medicare beneficiary hospital outpatient drug spending at 340B hospitals and non-340B hospitals. In 2018 and 2022, Milliman conducted an analysis to understand if similar patterns existed within a commercially insured population.

This new report:

• Provides updated findings, now using 2023 commercial data, to analyze drug spending among 340B hospitals for the commercially insured population.
• Expands the analysis to compare spending in Medicare using 2022 data, the most recent year of full-market data available.
• Includes comparisons across various member demographic characteristics, using the Medicare data.

This report was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).